Clinical and pharmacological group: & nbsp

Mucolytics and stimulators of motor function of the respiratory tract

Included in the formulation
  • Eufillin
    solution in / in 
    ATOLL, LLC     Russia
  • Eufillin
    solution in / in 
  • Eufillin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Eufillin
    solution in / in 
  • Eufillin
    solution in / in 
  • Eufillin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Eufillin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Eufillin
    solution in / in 
  • Eufillin
    pills inwards 
    ORGANICS, JSC     Russia
  • Eufillin
    pills inwards 
  • Eufillin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Eufillin
    pills inwards 
  • Eufillin
    solution in / in 
  • Eufillin
    pills inwards 
  • Eufillin
    pills inwards 
    ATOLL, LLC     Russia
  • Eufillin
    solution in / in 
  • Eufillin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Eufillin
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Eufillin
    solution in / in 
    VEROPHARM SA     Russia
  • Eufillin
    solution in / in 
    Mapichem AG     Switzerland
  • Eufillin
    solution in / in 
    GROTEKS, LLC     Russia
  • Eufillin
    pills inwards 
  • Eufillin AVEKSIMA
    pills inwards 
  • Euphyllin-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Euphyllin-ESCOM
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    Minimal chemist's assortment

    АТХ:

    R.03.D.A.05   Aminophylline

    Pharmacodynamics:

    Bronchodilator. It is the ethylenediamine salt of theophylline (which facilitates solubility and increases absorption). It has a bronchodilator effect due to a direct relaxing effect on the smooth muscles of the airways and blood vessels of the lungs. Reduces airway hyperreactivity associated with the late phase of the reaction caused by the inhalation of allergens, through an unknown mechanism that does not relate to inhibition of PDE or to blockade of adenosine. There are reports that aminophylline increases the number and activity of T-suppressors at peripheral blood. Increases mucociliary clearance, stimulates diaphragm contraction, improves the function of respiratory and intercostal muscles, stimulates the respiratory center,increases its sensitivity to carbon dioxide and improves alveolar ventilation, which ultimately leads to a reduction in the severity and frequency of episodes of apnea. Normalizing the respiratory function, contributes to the saturation of blood oxygen and reduce the concentration of carbon dioxide. Strengthens lung ventilation in hypokalemia. Has a stimulating effect on the activity of the heart, increases strength and heart rate, increases coronary blood flow and increases myocardial oxygen demand. Reduces the tone of blood vessels (mainly vessels of the brain, skin and kidneys). Has peripheral venodilating effect, reduces pulmonary vascular resistance, lowers pressure in a small circle of blood circulation. Increases renal blood flow, has a moderate diuretic effect. Expands extrahepatic biliary tract. Stabilizes the membranes of mast cells, inhibits the release of mediators of allergic reactions. It inhibits platelet aggregation (suppresses the platelet activation factor and PgE2α), increases the resistance of erythrocytes to deformation (improves the rheological properties of the blood), reduces thrombus formation and normalizes microcirculation.Has tocolytic effect, increases the acidity of gastric juice. In high doses, it has an epileptogenic effect.

    Pharmacokinetics:

    Aminophylline - a compound of theophylline with ethylenediamine, at physiological values ​​of pH releases free theophylline. Theophylline content in its salts: aminophylline anhydrous - 86%, aminophylline dihydrate - 79%.

    Indications:

    For oral administration: bronchoobstructive syndrome of various genesis (including bronchial asthma, COPD, including pulmonary emphysema, chronic obstructive bronchitis), hypertension in a small circulatory system, pulmonary heart, nocturnal apnea; acute and chronic heart failure (as part of combination therapy).

    For parenteral use: asthmatic status (additional therapy), apnea of ​​newborns, cerebrovascular insufficiency in ischemic type (as part of combination therapy), left ventricular failure with bronchospasm and respiratory impairment by the type of Cheyne-Stokes, edematous renal genesis (as part of complex therapy) ; acute and chronic heart failure (as part of combination therapy).

    VI.G40-G47.G47.3   Apnea in a dream

    IX.I26-I28.I27.0   Primary pulmonary hypertension

    IX.I26-I28.I27.9   Pulmonary heart disease, unspecified

    IX.I30-I52.I50.0   Congestive heart failure

    IX.I30-I52.I50.1   Left ventricular failure

    IX.I60-I69.I63   Cerebral infarction

    X.J40-J47.J43   Emphysema

    X.J40-J47.J44   Other chronic obstructive pulmonary disease

    X.J40-J47.J45   Asthma

    X.J40-J47.J46   Asthmatic status [status asthmaticus]

    X.J95-J99.J96   Respiratory failure, not elsewhere classified

    XIV.N00-N08.N04   Nephrotic syndrome

    XVI.P20-P29.P22   Breathing disorder in a newborn [distress]

    Contraindications:

    Hypersensitivity, including to other xanthine derivatives: pentoxifylline, caffeine, theobromine, ethylenediamine.

    Peptic ulcer of the stomach and duodenum (at the stage of exacerbation for oral forms), gastritis with high acidity, bleeding from the digestive tract in a recent anamnesis; severe AH or hypotension, severe tachyarrhythmias; hemorrhagic stroke, hemorrhage in the retina of the eye; epilepsy; porphyria.

    Carefully:

    With care - severe coronary insufficiency (acute phase of myocardial infarction, angina pectoris), widespread atherosclerosis of the vessels, GOKMP, frequent ventricular extrasystole, CHF, increased convulsive alertness, hepatic and / or renal insufficiency,stomach ulcer and duodenal ulcer in the anamnesis, bleeding from the gastrointestinal tract, uncontrolled hypothyroidism (possibility of cumulation), thyrotoxicosis, prolonged hyperthermia, gastroesophageal reflux, prostatic hypertrophy, pregnancy, breast-feeding, elderly age, children's age (especially for oral forms), diarrhea and rectal disease (for rectal administration).

    Pregnancy and lactation:

    Pregnancy

    Recommendations FDA category C. Possible application for life.

    Lactation

    Less than 1% of the administered dose penetrates into breast milk, which can cause increased excitability in the infant. Possible application for vital indications.

    Dosing and Administration:

    Parenteral. Asthmatic status: as part of complex therapy; small additional effect for adults - IV infusion 720-750 mg, - and for children.

    Apnea of ​​newborns: injected on a nasogastric tube at an initial dose of 5 mg / kg, maintaining a dose of 2 mg / kg in 2 divided doses; the duration of treatment is several weeks or months. In preterm infants, the loading dose is 5-6 mg / kg intravenously, then 1.5 mg / kg every 8 hours for 48 hours.

    Violation of cerebral circulation by ischemic type (as part of complex therapy, insufficient evidence, the effect is not revealed).

    Edema syndrome with kidney disease (as part of complex therapy).

    Left ventricular failure, occurring with bronchospasm and Cheyne-Stokes breathing.

    Inside.

    Bronchoobstructive syndrome of various origin: bronchial asthma (a means of choice for physical stress asthma and an adjunct in other forms), COPD (emphysema, chronic obstructive bronchitis). Pulmonary hypertension, pulmonary heart.

    Nocturnal apnea (insufficient evidence, no effect).

    Intravenously adults with urgent conditions: 6 mg / kg, previously dissolved in 10-20 ml of 0.9% sodium chloride solution, injected slowly for 5 minutes.

    Intramuscularly to adults: 100-500 mg / day.

    Inside adults: 100-200 mg 3-4 times a day, if necessary, increase the dose every 3 days.

    Inside adults in the form of prolonged forms: the initial dose of 175 mg every 12 hours, then the dose is increased every 3 days to obtain the optimal therapeutic effect.

    In the acute phase of COPD, an adult: an initial dose of 5-6 mg / kg (with a further increase in dose for every 0.5 mg / kg, the concentration of aminophylline in the blood increases by 1 μg / ml). Concentration in the blood should not exceed 20 mcg / ml. The maintenance dose for smokers is 4 mg / kg every 6 hours, for non-smokers and patients with liver disease - 2 mg / kg every 8 hours.

    Outside the exacerbation of COPD, an initial dose of 6-8 mg / kg / day (maximum 400 mg / day) in 3-4 divided doses is possible, increasing the dose by 25% every 2-3 days to a maximum of 13 mg / kg / day (900 mg / day).

    Rectally in the form of microclysters: 0.24-0.48 g in 20-25 ml of warm water; children - according to age.

    Maximum doses for adults inside, intramuscularly and rectally: single-dose 0.5 g daily, 1.5 g; intravenously: single - 0.25 g, daily - 0.5 g.

    Use in children

    For maintenance therapy, asthma is taken internally; dosing according to the manufacturer's instructions.

    For relief of a severe asthma attack.

    Intravenously sprayed for 20 minutes (provided that before the introduction of the patient did not take theophylline). 1 month to 18 years: 5 mg / kg (maximum 500 mg), then - intravenous infusion.

    Intravenous infusion (dose is selected by determining the concentration of theophylline in the blood plasma). 1 month to 9 years: 1 mg / kg / h. 9-16 years: at 800 mcg / kg / h. 16-18 years: at 500 mcg / kg / h.

    The optimal effective concentration of theophylline in plasma for bronchial asthma is 10-20 mg / l. Children receiving theophylline or aminophylline inside, usually appoint aminophylline intravenously only in the case when it is possible to control the concentration of theophylline in the plasma.

    For the treatment of apnea of ​​newborns. Intravenously spray for 20 minutes: an initial dose of 6 mg / kg, then - 2.5 mg / kg every 12 hours, increasing if necessary up to 3.5 mg / kg every 12 hours.

    The optimal concentration of theophylline in plasma in the treatment of apnea of ​​newborns is 8-12 mg / l. Children receiving theophylline or aminophylline inside, usually appoint aminophylline intravenously only with the ability to control the concentrations of theophylline in plasma.

    In the acute phase of the disease, the initial dose is 5-6 mg / kg, and the maintenance dose (mg / kg) is calculated by the following formula. Up to 6 months: 0,07 × age in weeks + 1,7 (every 8 hours). 6-12 months: 0.05 × age in weeks + 1.25 (every 6 hours). 1-9 years: 5 mg / kg every 6 hours 9-12 years: 4 mg / kg every 6 hours 12-16 years: 3 mg / kg every 6 hours.

    In the absence of exacerbation, the initial dose of 16 mg / kg / day (maximum 400 mg / day) in 3-4 divided doses can be increased by 25% every 2-3 days to a maximum daily dose, which is up to 1 year 0.3 × age in weeks + 8. In 1-9 years - 22 mg / kg. In 9-12 years - 20 mg / kg.At the age of 12-16 years - 18 mg / kg. At the age of 16-18 - 13 mg / kg.

    Intramuscularly - 15 mg / kg / day.

    Intravenous (duration of parenteral administration does not exceed 14 days). Less than 3 months: 30-60 mg / day. 4-12 months: 60-90 mg / day. 2-3 years: 90-120 mg. 4-7 years: 120-240 mg. 8-18 years: 250-500 mg / day.

    The largest doses for children inside, intramuscularly and rectally: single dose - 7 mg / kg, daily - 15 mg / kg; intravenously: single dose - 3 mg / kg.

    Side effects:

    Tremor, increased excitability, headache, insomnia, tachycardia, nausea and / or vomiting, increased diuresis, gastroesophageal reflux. Dermatitis, hypersensitivity to ethylenediamine, rash, peeling of the skin. Possible hypotension and cardiac arrest after rapid administration of aminophylline through a catheter in the central vein.

    Overdose:

    anorexia, diarrhea, nausea, vomiting, epigastric pain, gastrointestinal bleeding, tachypnea, face hyperemia, tachycardia, ventricular arrhythmias, insomnia, anxiety, photophobia, generalized convulsions.

    Treatment: withdrawal of the drug, stimulation of its excretion from the body (gastric lavage, forced diuresis, hemosorption, plasmosorption, hemodialysis, peritoneal dialysis), symptomatic therapy

    Interaction:

    Pharmaceutical incompatibility: precipitates in acidic media; is incompatible with certain drugs, therefore, no additives should be added directly to the aminophylline bottle for intravenous infusions; is incompatible with amiodarone, hydralazine, diltiazem, dobutamine, ondansetron and ciprofloxacin if they are poured into one opening of the device that is intended for intravenous administration.

    Special instructions:

    Intramuscular administration is not recommended: the drug can accumulate at the injection site, it can be absorbed more slowly and cause pain.

    The injection form of aminophylline for intravenous administration is prepared using isotonic sodium chloride solution, dextrose.

    To stop the attack of bronchial asthma in adults, routine intravenous administration of aminophylline in addition to treatment with β2-adrenomimetics is not indicated, since the use of aminophylline does not enhance bronchodilation and increases the risk of side effects.

    In case of severe exacerbation of bronchial asthma in children (FEV1 35-40% of the norm) in addition to treatment with systemic glucocorticoids, inhaled β2-adrenomimetics and anticholinergics, it is necessaryintravenous injection of aminophylline in a loading dose of 6-10 μg / kg followed by intravenous infusion. This leads to an additional increase in FEV1 by 9%, but increases the likelihood of vomiting by 4 times.

    Based on the results of existing studies, with exacerbation of COPD, the use of methylxanthines (aminophylline, doxophylline, theophylline) does not cause a statistically significant improvement in lung function or a reduction in symptoms, but is accompanied by significantly increased side effects.

    With ischemic stroke and nocturnal sleep apnea in adults, the effect of methylxanthines has not been proven. The findings are based on a few studies; As information accumulates, changes are possible

    Correction of the dosage regimen of aminophylline may be required for heart failure, violations of liver function, chronic alcoholism, fever, acute respiratory disease.

    Older patients may need a dose reduction.

    When you replace the drug form of aminophylline with another, you need to monitor and monitor the concentration of theophylline in the blood plasma.

    Aminophylline is not used simultaneously with other xanthine derivatives.During the period of treatment, avoid eating foods containing xanthine derivatives (strong coffee, tea).

    With caution apply simultaneously with anticoagulants, with other derivatives of theophylline or purine.

    You should avoid simultaneous use with beta-blockers.

    Aminophylline should not be used concomitantly with glucose solution

    Instructions
    Up